血清TGF-β1、Bcl-2及食管鳞癌组织MTDH表达水平与食管鳞癌患者临床预后的相关性

摘要/Abstract

摘要： 目的：探讨血清转化生长因子-β1（TGF-β1）、B淋巴细胞瘤-2蛋白（Bcl-2）及食管鳞癌组织异黏蛋白（MTDH）表达水平与食管鳞癌患者临床预后的相关性。方法：以我院于2019年4月至2021年4月收治的食管鳞癌患者88例为研究对象。收集患者临床病理特征及血清TGF-β1、Bcl-2及食管鳞癌组织MTDH表达水平，分析不同病理特征患者血清TGF-β1、Bcl-2及食管鳞癌组织MTDH表达水平的差异。随访2年，按是否死亡将患者分为存活组、死亡组，比较两组患者血清TGF-β1、Bcl-2及食管鳞癌组织MTDH表达水平。经Spearson相关分析，分析血清TGF-β1、Bcl-2及食管鳞癌组织MTDH表达水平与临床预后的相关性。经受试者工作曲线（ROC）评估血清TGF-β1、Bcl-2及食管鳞癌组织MTDH表达水平预测食管鳞癌患者预后的价值。结果：Ⅲ+Ⅳ期食管鳞癌患者TGF-β1、Bcl-2、MTDH表达水平高于Ⅰ+Ⅱ期患者；低分化食管鳞癌患者TGF-β1、Bcl-2、MTDH表达水平高于中高分化患者；存在淋巴结转移食管鳞癌患者TGF-β1、Bcl-2、MTDH表达水平高于无淋巴结转移患者（P<0.05）。死亡组患者TGF-β1、Bcl-2、MTDH表达水平高于存活组（P<0.05）。Spearson分析结果显示，血清TGF-β1、Bcl-2及组织MTDH表达水平与TNM分期、分化程度、淋巴结转移呈正相关，r值0.264~0.523不等（P<0.05），与预后呈中高强度正相关，r值依次为0.532、0.478、0.636（P<0.05）。ROC结果显示：TGF-β1、Bcl-2、MTDH表达水平评估食管鳞癌预后预测价值较佳，AUC值依次为0.874、0.793、0.893；以MTDH预测价值最佳，灵敏度、特异度分别为93.70%、78.57%，此时最佳截断值为1.45。结论：食管鳞癌患者血清TGF-β1、Bcl-2及食管鳞癌组织MTDH表达水平与临床病理特征及预后均呈正相关，通过监测TGF-β1、Bcl-2及MTDH表达便于及时了解病情进展，且对预后评估具有较好预测价值。

关键词: 食管鳞癌, 转化生长因子-β1, B淋巴细胞瘤-2蛋白, 异黏蛋白, 预后

Abstract: Objective： To investigate the correlation of the expression levels of serum transforming growth factor-β1 (TGF-β1)， B-lymphoblastoma-2 (Bcl-2) and metadherin (MTDH) in esophageal squamous cell carcinoma tissues with clinical prognosis of the patients. Methods： A total of 88 patients with esophageal squamous cell carcinoma admitted to our hospital from April 2019 to April 2021 were selected as the research objects. The clinicopathological features， serum TGF-β1， Bcl-2 expression levels and MTDH expression level in esophageal squamous cell carcinoma tissues were collected and analyzed. The patients were followed up for 2 years and were divided into the survival group and the death group according to whether they died or not. The expression levels of serum TGF-β1， Bcl-2 and MTDH in esophageal squamous cell carcinoma tissues were compared between the two groups. The correlation of serum TGF-β1， Bcl-2 levels and MTDH expression level in esophageal squamous cell carcinoma tissues with clinical prognosis of the patients was analyzed by Spearson analysis.The value of serum TGF-β1， Bcl-2 levels and MTDH expression level in esophageal squamous cell carcinoma tissues in predicting prognosis of patients with esophageal squamous cell carcinoma was evaluated by receiver operating curve (ROC). Results： The expression levels of TGF-β1， Bcl-2 and MTDH in esophageal squamous cell carcinoma patients in stage Ⅲ+Ⅳ were higher than those in stage Ⅰ+Ⅱ(P<0.05).The expression levels of TGF-β1， Bcl-2 and MTDH in low-differentiated esophageal squamous cell carcinoma patients were higher than those of middle and high-differentiated esophageal squamous cell carcinoma patients(P<0.05). The expression levels of TGF-β1， Bcl-2 and MTDH in patients with lymph node metastasis were higher than those without lymph node metastasis (P<0.05). The expression levels of TGF-β1， Bcl-2 and MTDH of patients in the death group were higher than those in the survival group (P<0.05). Spearson analysis showed that the expression levels of TGF-β1， Bcl-2 and MTDH were positively correlated with the TNM stage， differentiation degree and lymph node metastasis with r values ranging from 0.264 to 0.523 (P<0.05)， and were positively correlated with the prognosis， with r values of 0.532， 0.478 and 0.636 (P<0.05). ROC results showed that the expression levels of TGF-β1， Bcl-2 and MTDH had good prognostic value in evaluating the prognosis of esophageal squamous cell carcinoma， and the AUC values were 0.874， 0.793 and 0.893 respectively. MTDH had the best prognostic value， and the sensitivity and specificity were 93.70% and 78.57% respectively， and the optimal cut-off value was 1.45. Conclusion： The expression levels of serum TGF-β1， Bcl-2 and MTDH in esophageal squamous cell carcinoma tissues are positively correlated with the clinicopathological features and prognosis of patients with esophageal squamous cell carcinoma. Monitoring the expression levels of TGF-β1， Bcl-2 and MTDH facilitate timely understanding of the disease progression， and has good predictive value for prognosis evaluation.

Key words: font-size:medium, ">Esophageal squamous cell carcinoma； TGF-β1；Bcl-2； MTDH； Prognosis

中图分类号:

R735.1

王伟, 刘振辉. 血清TGF-β1、Bcl-2及食管鳞癌组织MTDH表达水平与食管鳞癌患者临床预后的相关性[J]. 中国医药导刊, 2023, 25(10): 1023-1028.

WANG Wei, LIU Zhenhui. Correlation of the Expression Levels of Serum TGF-β1， Bcl-2 and MTDH in Esophageal Squamous Cell Carcinoma Tissues with Clinical Prognosis#br#[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2023, 25(10): 1023-1028.

参考文献

[1]Uhlenhopp DJ， Then EO， Sunkara T， et al. Epidemiology of esophageal cancer： update in global trends， etiology and risk factors[J]. Clin J Gastroenterol， 2020， 13(6)：1010-1021.
[2]Morgan E， Soerjomataram I， Rumgay H， et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040： new estimates from GLOBOCAN 2020[J]. Gastroenterology， 2022， 163(3)：649-658.
[3]Niu C， Liu Y， Wang J， et al. Risk factors for esophageal squamous cell carcinoma and its histological precursor lesions in China： a multicenter cross-sectional study[J]. BMC Cancer， 2021， 21(1)：1034.
[4]Zeng H， Chen W， Zheng R， et al. Changing cancer survival in China during 2003-15： a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health， 2018， 6(5)：e555-e567.
[5]Hao Y， Baker D， Ten Dijke P. TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis[J]. Int J Mol Sci， 2019， 20(11)：2767.
[6]Lu C， Yang Z， Yu D， et al. RUNX1 regulates TGF-β induced migration and EMT in colorectal cancer[J]. Pathol Res Pract， 2020， 216(11)：153142.
[7]李玲玉，彭戴君，杨海生，等. TGF-β1通过介导上皮-间叶转化促进甲状腺乳头状癌的侵袭和淋巴结转移[J]. 临床与实验病理学杂志， 2023， 39(2)：188-194.
[8]尹博，王兵，牛磊，等. VEGF和Bcl-2在食管癌患者血清中的表达水平及其临床意义[J]. 癌症进展， 2019， 17(2)：154-157.
[9]Jin L， Chen Y， Cheng D， et al. YAP inhibits autophagy and promotes progression of colorectal cancer via upregulating Bcl-2 expression[J]. Cell Death Dis， 2021， 12(5)：457.
[10]Elnaggar GN， El-Hifnawi NM， Ismail A， et al. Micro RNA-148a targets Bcl-2 in patients with non-small cell lung cancer[J]. Asian Pac J Cancer Prev， 2021， 22(6)：1949-1955.
[11]Shi X， Wang X. The role of MTDH/AEG-1 in the progression of cancer[J]. Int J Clin Exp Med， 2015， 8(4)：4795-4807.
[12]Chu PY， Wang SM， Chen PM， et al. Expression of MTDH and IL-10 is an independent predictor of worse prognosis in ER-negative or PR-negative breast cancer patients[J]. J Clin Med， 2020， 9(10)：3153.
[13]国家卫生健康委员会.食管癌诊疗规范(2018年版) [J]. 肿瘤综合治疗电子杂志， 2019， 5(2)：50-86.
[14]张燕，李相磊，张红蕊，等. 食管癌患者血清B细胞淋巴瘤因子-2，转化生长因子-β1及血管内皮生长因子水平与临床病理特征的相关性[J]. 中国卫生检验杂志， 2021， 31(17)：2097-2101.
[15]Stahl M， Mariette C， Haustermans K， et al. Oesophageal cancer： ESMO Clinical Practice Guidelines for diagnosis， treatment and follow-up[J]. Ann Oncol， 2016， 27(5)：50-57.
[16]Amin MB， Greene FL， Edge SB， et al. The Eighth Edition AJCC Cancer Staging Manual： Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging[J]. CA Cancer J Clin， 2017， 67(2)：93-99.
[17]Zhang X， Wang Y， Meng L. Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma： new opportunities towards molecularly targeted therapy[J]. Acta Pharm Sin B， 2022， 12(3)：1054-1067.
[18]Yang J， Liu X， Cao S， et al. Understanding esophageal cancer： the callenges and opportunities for the next decade[J]. Front Oncol， 2020， 10：1727.
[19]李胜磊，王昆仑，杨晖，等. 放化疗与单独化疗对ⅣB期食管鳞癌生存期影响的比较[J]. 中华放射肿瘤学杂志， 2022， 31(10)：884-890.
[20]Reichenbach ZW， Murray MG， Saxena R， et al. Clinical and translational advances in esophageal squamous cell carcinoma[J]. Adv Cancer Res， 2019， 144：95-135.
[21]江始源，司富春，王文彬，等. 食管癌肿瘤微环境中的癌相关细胞研究进展[J]. 中国实验方剂学杂志， 2022， 28(4)：262-270.
[22]Morikawa M， Derynck R， Miyazono K. TGF-β and the TGF-β family： context-dependent roles in cell and tissue physiology[J]. Cold Spring Harb Perspect Biol， 2016， 8(5)：a021873.
[23]郭艳丽，牛云峰，梁晓亮，等. TGF-β诱导的linc01503促进食管鳞状细胞癌细胞的增殖，侵袭及EMT过程[J]. 中国肿瘤生物治疗杂志， 2020， 27(7)：764-769.
[24]Wang F， Zhang C， Cheng H， et al. TGF-β-induced PLEK2 promotes metastasis and chemoresistance in oesophageal squamous cell carcinoma by regulating LCN2[J]. Cell Death Dis， 2021， 12(10)：901.
[25]胡述提，王铮. 外周血D-D及TGF-β1和叶酸水平在食管癌手术前后变化及与预后的相关性研究[J]. 医药论坛杂志， 2021， 42(5)：30-33， 37.
[26]袁丽，张立玮，尔丽绵，等. Bcl-2基因多态性与食管和贲门癌的关联研究[J]. 中华预防医学杂志， 2019， 53(11)：1119-1123.
[27]Chen Y， Wang D， Peng H， et al. Epigenetically upregulated oncoprotein PLCE1 drives esophageal carcinoma angiogenesis and proliferation via activating the PI-PLCε-NF-κB signaling pathway and VEGF-C/ Bcl-2 expression[J]. Mol Cancer， 2019， 18(1)：1.
[28]陈恋恋，朱春凯，郑培明. Bcl-2、miR-451和Th17细胞在食管癌中的诊断价值及其与复发的关系[J]. 肿瘤防治研究， 2021， 48(1)：38-42.
[29]Sriramulu S， Sun XF， Malayaperumal S， et al. Emerging role and clinicopathological significance of AEG-1 in different cancer types： aconcise review[J]. Cells， 2021， 10(6)：1497.
[30]Luo L， Tang H， Ling L， et al. LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer[J]. Oncogene， 2018， 37(47)：6166-6179.
[31]Jia Y， Tian C， Wang H， et al. Long non-coding RNA NORAD/miR-224-3p/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of β-catenin[J]. Mol Cancer， 2021， 20(1)：162.
[32]Luo Y， Zhang X， Tan Z， et al. Astrocyte elevated gene-1 as a novel clinicopathological and prognostic biomarker for gastrointestinal cancers： a meta-analysis with 2999 patients[J]. PLoS One， 2015， 10(12)：e0145659.

快速检索引用检索图表检索高级检索